News coverage about T2 Biosystems (NASDAQ:TTOO) has trended somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. T2 Biosystems earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave media headlines about the medical equipment provider an impact score of 47.1099451353192 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
Shares of T2 Biosystems (NASDAQ TTOO) traded down $0.22 during trading hours on Friday, reaching $5.20. 250,823 shares of the company were exchanged, compared to its average volume of 347,382. The company has a debt-to-equity ratio of 2.25, a quick ratio of 5.28 and a current ratio of 5.40. The firm has a market capitalization of $194.17, a P/E ratio of -2.74 and a beta of 1.48. T2 Biosystems has a 1 year low of $2.50 and a 1 year high of $6.99.
T2 Biosystems (NASDAQ:TTOO) last announced its quarterly earnings data on Thursday, November 2nd. The medical equipment provider reported ($0.45) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.49) by $0.04. The firm had revenue of $1.11 million during the quarter, compared to the consensus estimate of $1.10 million. T2 Biosystems had a negative net margin of 1,497.70% and a negative return on equity of 244.82%. The business’s revenue was up 2.8% on a year-over-year basis. analysts predict that T2 Biosystems will post -1.85 earnings per share for the current fiscal year.
A number of equities analysts recently issued reports on TTOO shares. Zacks Investment Research raised T2 Biosystems from a “sell” rating to a “hold” rating in a report on Thursday, October 5th. HC Wainwright started coverage on shares of T2 Biosystems in a research report on Wednesday, October 18th. They issued a “buy” rating and a $8.00 price objective for the company. Finally, Canaccord Genuity restated a “buy” rating and issued a $6.00 price objective on shares of T2 Biosystems in a research report on Monday, October 30th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. T2 Biosystems presently has an average rating of “Hold” and a consensus target price of $6.54.
WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/13/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-t2-biosystems-ttoo-share-price.html.
About T2 Biosystems
T2 Biosystems, Inc is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL).
Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.